Arsanis, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.
The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.
“The ASN300 program is currently in preclinical development. As part of this program, Arsanis is developing monoclonal antibodies, including ASN-5, which have demonstrated rapid and targeted activity through various modes of action and provide high efficacy in relevant animal models of severe K. pneumoniae infections.” Read the following article
Company Website: http://investors.arsanis.com